Tonix Pharmaceuticals Announces Positive Pre-IND Meeting with FDA for TNX-102 SL for the Treatment of Major Depressive Disorder
Provided By GlobeNewswire
Last update: Sep 18, 2025
Tonix anticipates filing the IND application in the fourth quarter of 2025
TNX-102 SL is a potential first-in-class treatment for targeting the disturbed sleep associated with depression
Read more at globenewswire.comNASDAQ:TNXP (10/2/2025, 2:37:22 PM)
24.33
+0.38 (+1.59%)
Find more stocks in the Stock Screener
